Forxiga generics continue being released in the Korean mkt

Salt-modified drugs listed after expiry of the first generic exclusivity period

Samjin Pharamcetucial’s Dapozin Tab 5mg, Kyungbo Pharm’s Dapakhan Tab 10mg will be reimbursed from January

8 new dapagliflozin anhydrous lactose mixture+metformin combinations are listed as well

Generic versions of Forxiga’s salt-modified drug, which were released in April, will be reimbursed from next month.

 

These generics were released later than other Forxiga generics because the original salt-modified drug obtained first generic exclusivity in Korea, banning the sales of other salt-modified drugs that contain the same ingredient until January 7 next year.

 

According to industry sources on the 19th, Foxiga’s salt-modified generics, including Samjin Pharamcetucial’s Dapozin Tab 5mg, Kyungbo Pharm’s Dapakhan Tab 10mg, will be listed next month Fixe single-agent and 8 combination drugs will be listed at the time.

 

Samjin Pharamcetucial’s Dapozin Tab 5mg is a non-salt dapagliflozin 5mg product.

 

Chong Kun Dang’s Exiglu Tab 5mg is the only other same-ingredient and dosage drug available with reimbursement in Korea, but, Chong Kun acquired the first generic exclusivity for its Exiglu upon release and banned other same-ingredient same-dose drugs from being sold in the market until January 7 next year.

 

To avoid this, Samjin Pharamcetucial released a different dosage of the same ingredient drug, Dapozin Tab 10mg, in April this year.

 

Kyungbo Pharm’s Dapakhan Tab 10mg is a 15.27mg dapagliflozin anhydrous lactose mixture.

 

The 5 other generics with the same ingredient had obtained first generic exclusivity at the same time.

 

Therefore, the same-ingredient same-dosage formulation drugs like Dapakhan 10mg can only be sold from January 8th next year.

 

In addition to Dapakhan 10mg, Guju Pharma’s ‘Dafarizin Tab.

 

10mg,’ Unimed Pharm’s ‘Sugapa Tab.

 

10mg,’ and Pharmgen Science’s ‘Daflozin Tab 10mg’ will also be listed for reimbursement on January 8th.

 

With the exception of Daflozin Tab 10 mg, whose company decided to select a price, the other four single-agent drugs received a 59.5% markup to the highest price of the same ingredient drugs.

 

However, the premium pricing is only applied temporarily for 3 months as their price will be adjusted in line with the price adjustment of the original salt-modified drug on April 8 next year.

 

In the case of combination drugs, new salt-modified combination drugs will be listed for the first time.

 

Eight items, including Sinil Pharm’s ‘Forxigly Duo ER Tab 10/500mg', will be reimbursed from next month.

 

Forxigly Duo ER Tab 10/500 mg contains 15.27 mg of dapagliflozin anhydrous lactose mixture.

 

and 500 mg of metformin hydrochloride, and there is no other equivalent currently listed on the reimbursement list.

 

Along with Sinil, HLB Pharm, Kyungbo Pharm, and Samjin Pharm will also be granted reimbursement for 2 different dosage forms of the combination each next month.

 

Meanwhile, 64 Korean pharmaceutical companies have entered the Foxiga generic market so far.